NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (www.kamada.com), a biopharmaceutical company specializing in the development, manufacturing and marketing of specialty, life-saving biopharmaceuticals, announced today that it has signed a $4 million private equity investment agreement with Shavit Capital Fund, pending the approval of the audit committee, the board of directors and a general assembly to be held during the months of March & April. The stock price will represent the 45 days of trade preceding the day of signature with a premium of 3%. The final price will be about 8.8% higher than the stock price on the day the agreement is signed between the two sides.
